[Benefits of spironolactone as the optimal treatment for drug resistant hypertension. Pathway-2 trial review]
- PMID: 27363610
- DOI: 10.1016/j.hipert.2016.05.003
[Benefits of spironolactone as the optimal treatment for drug resistant hypertension. Pathway-2 trial review]
Abstract
Pathway-2 is the first randomised, double-blind and crossover trial that compares spironolactone as a fourth drug with alfa-blocker, beta-blocker and placebo. This study shows that spironolactone is the drug with more possibilities of success for the management of patients with difficult-to-treat hypertension in patients with a combination of three drugs and poor control. The results validate the widespread treatment with mineralocorticoid receptor antagonists in resistant hypertension.
Keywords: Antagonistas del receptor de mineralocorticoides; Denervación renal; Espironolactona; Hipertensión arterial resistente; Mineralocorticoid receptor antagonists; Renal denervation; Resistant hypertension; Spironolactone.
Copyright © 2016 SEH-LELHA. Publicado por Elsevier España, S.L.U. All rights reserved.
Comment on
-
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.Lancet. 2015 Nov 21;386(10008):2059-2068. doi: 10.1016/S0140-6736(15)00257-3. Epub 2015 Sep 20. Lancet. 2015. PMID: 26414968 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
